【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs: Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. An Introduction To Ophthalmic Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Ophthalmic Treatments – An Industry Overview
2.2 The Human Eyes – Structurally Delicate And Functionally Intricate Organs
2.3 The Global Burden Of Eye Disease
2.4 Ophthalmic Drugs: Market Segmentation
2.5 Glaucoma: A Major Cause Of Vision Loss
2.5.1 A Classification Of Glaucoma
2.5.1.1 Primary Open-Angle Glaucoma
2.5.1.2 Acute Angle-Closure Glaucoma
2.5.1.3 Congenital Glaucoma
2.5.1.4 Secondary Glaucoma
2.5.1.5 Normal-Tension Glaucoma
2.5.1.6 Ocular Hypertension
2.5.2 Risk Factors For Glaucoma
2.5.3 Diagnosis Of Glaucoma
2.5.4 Drug Treatment Of Glaucoma
2.5.5 Laser Treatment And Surgery For Glaucoma
2.6 Age-Related Macular Degeneration (AMD)
2.6.1 Dry (non-exudative) AMD
2.6.2 Wet (exudative) AMD
2.6.3 Risk Factors For AMD
2.6.4 Diagnosis of AMD
2.6.5 Treatment of AMD
2.7 Diabetic Retinopathy (DR)
2.7.1 Diagnosis Of Diabetic Retinopathy
2.7.2 Treatment Of Diabetic Retinopathy
2.8 Ocular Allergy And Allergic Conjunctivitis
2.8.1 Diagnosis Of Ocular Allergy
2.8.2 Treatment Of Ocular Allergy
2.9 Ocular Inflammatory Disease
2.9.1 Treatment Of Ocular Inflammatory Disease
2.10 Eye Infections
2.10.1 Treatment Of Eye Infections
2.11 Dry Eye Syndrome
2.11.1 Treatment of Dry Eye Syndrome
2.12 Phases of Clinical Trials
2.13 Ophthalmic Drugs: Market Definition In This Report
3. The Global Ophthalmic Drugs Market, 2015-2025
3.1 The Global Ophthalmic Drugs Market: Market Overview
3.2 Categorisation Of The Global Ophthalmic Drugs Market
3.3 The Global Ophthalmic Drugs Market In 2014
3.4 The Global Ophthalmic Drugs Market: Market Forecast 2015-2025
3.5 Ophthalmic Drugs: Changing Market Shares By Sector 2015-2025
4. The Retinal Disorder Drugs Market: Market Analysis And Forecast 2015-2025
4.1 Leading Products In The Retinal Disorder Drugs Market, 2014
4.2 Retinal Disorders: Market Trends And Developments, 2015
4.2.1 The Rise And Rise Of Lucentis
4.2.2 The Debate Around Off-Label Avastin Use And The Role Of Novartis And Roche
4.2.3 How Likely Is Avastin’s Expansion Into Age-Related Macular Degeneration?
4.2.4 Jetrea: Underwhelming Sales And ThromboGenics’ Efforts To Reverse It
4.2.5 Drug/Device Combination Products Entering The Market
4.2.6 Does Regenerative Medicine Have A Successful Future In Ophthalmics?
4.3 Retinal Disorder Drugs: Market Forecast 2015-2025
4.3.1 Retinal Disorder Drugs: Changing Market Shares By Leading Drugs 2015-2025
4.4 Leading Drugs For The Treatment Of Retinal Disorders
4.5 Lucentis (ranibizumab) – Roche/ Novartis
4.5.1 Lucentis: Sales Forecast 2015-2025
4.5.2 Less Frequent Dosing Approved In US For Lucentis
4.5.3 New Indications For Lucentis
4.5.4 Possible Combination Therapy Involving Lucentis
4.6 Eylea (aflibercept) – Regeneron/ Bayer/ Santen
4.6.1 Recent Approvals For Eylea
4.6.2 Eylea: Sales Forecast 2015-2025
4.6.3 Possible Combination Therapies Involving Eylea
4.7 Avastin (bevacizumab) – Roche
4.7.1 Avastin: Sales Forecast 2015-2025
4.7.2 Compounding Pharmacies And Safety Risks
4.8 Visudyne (verteporfin) – Valeant/ Novartis
4.8.1 Visudyne: Sales Forecast 2015-2025
4.9 Jetrea (ocriplasmin) – ThromboGenics/ Novartis
4.9.1 Jetrea: Recent Sales Performance
4.9.2 Clinical Study Plans For Jetrea
4.9.3 Jetrea: Sales Forecast 2015-2025
4.9.4 Possible Acquisition Move On ThromboGenics
4.9.5 R&D Agreements With Eleven Biotherapeutics and Bicycle Therapeutics
4.10 Other Retinal Disorder Drugs
4.10.1 Iluvien (fluocinolone implant) – Alimera Sciences
4.10.2 Ozurdex (dexamethasone implant) – Allergan
4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2015-2025
5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis And Forecast 2015-2025
5.1 Leading Products In The Allergic, Inflammatory And Infective Drugs Market, 2014
5.1.1 Allergic, Inflammatory And Infective Drugs: Market Trends And Developments, 2015
5.1.2 The Growth Prospects For Allergic, Inflammatory And Infective Drugs
5.1.3 Topical NSAIDs Launched: Prolensa and Ilevro
5.2 Allergic, Inflammatory And Infective Drugs: Market Forecast 2015-2025
5.2.1 Allergic, Inflammatory And Infective Drugs: Changing Market Shares By Leading Drugs 2015-2025
5.3 Leading Drugs For The Treatment Of Allergic, Inflammatory And Infective Ophthalmic Conditions
5.4 Patanol And Pataday (olopatadine) – Alcon (Novartis)
5.4.1 Pataday: Sales Forecast 2015-2025
5.4.2 Impending Generic Competition For Patanol And Pataday
5.4.3 Approval Of Pazeo Solution
5.4.4 Patanol: Sales Forecast 2015-2025
5.5 Vigamox (moxifloxacin) – Alcon (Novartis)
5.5.1 Intensifying Competition And Generics Drug Challenge To Vigamox
5.5.2 Moxeza: A Next-Generation Form of Vigamox
5.5.3 Vigamox: Sales Forecast 2015-2025
5.6 TobraDex (tobramycin/dexamethasone) – Alcon (Novartis)
5.6.1 The Development And Commercialisation Of TobraDex ST
5.6.2 TobraDex: Sales Forecast 2015-2025
5.7 Bromday (bromfenac) – Valeant
5.7.1 Prolensa: A New Formulation Of Bromfenac
5.7.2 Competition From Ilevro/Nevanac
5.7.3 Bromday: Sales Forecast 2015-2025
5.8 Cravit (levofloxacin) – Santen
5.8.1 Cravit: Sales Forecast 2015-2025
5.9 Acular (ketorolac) – Allergan (Actavis)
5.9.1 Acular: Sales Forecast 2015-2025
5.10 AzaSite (azithromycin) – Akorn
5.10.1 AzaSite: Sales Forecast 2015-2025
5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2015-2025
6. Glaucoma Drugs Market: Market Analysis And Forecast 2015-2025
6.1 Glaucoma Drugs: Market Overview
6.1.1 Leading Products In The Glaucoma Drugs Market, 2014
6.2 Glaucoma Drugs: Market Trends And Developments, 2015
6.2.1 Patent Expiration: A Major Restraint For Glaucoma Drugs
6.2.2 Preservative-Free Formulation Trends
6.2.3 Innovation In Treatments For Glaucoma
6.2.4 Simbrinza: First Beta-Blocker-Free Combination
6.3 Glaucoma Drugs: Market Forecast 2015-2025
6.3.1 Glaucoma Drugs: Changing Market Shares By Leading Drugs 2015-2025
6.4 Leading Drugs For The Treatment Of Glaucoma
6.5 Lumigan And Ganfort (bimatoprost) – Allergan (Actavis)
6.5.1 Lumigan And Ganfort: Sales Forecast 2015-2025
6.6 Xalatan And Xalacom (latanoprost) – Pfizer
6.6.1 Xalatan/Xalacom: Sales Forecast 2015-2025
6.7 Travatan/Travatan Z And DuoTrav (travoprost) – Novartis
6.7.1 Travatan/Travatan Z And DuoTrav: Sales Forecast 2015-2025
6.8 Alphagan/Alphagan P And Combigan (brimonidine) – Allergan
6.8.1 Alphagan/Alphagan P And Combigan: Sales Forecast 2015-2025
6.9 Trusopt And Cosopt/Cosopt PF (dorzolamide) – Merck/ Santen
6.9.1 Divestment Agreement With Santen And Akorn
6.9.2 Trusopt: Sales Forecast 2015-2025
6.9.3 Cosopt And Cosopt PF: Sales Forecast 2015-2025
6.10 Azopt (brinzolamide) – Novartis
6.10.1 Azopt: Sales Forecast 2015-2025
6.11 Tapros (tafluprost) – Santen
6.11.1 Tapros: Sales Forecast 2015-2025
6.12 Zioptan (tafluprost) – Akorn
6.12.1 Zioptan: Sales Forecast 2015-2025
6.13 Other Glaucoma Drugs: Sales Forecast 2015-2025
7. Dry Eye Drugs Market: Market Analysis And Forecast 2015-2025
7.1 Dry Eye Drugs: Market Overview
7.1.1 Leading Products In The Dry Eye Drugs Market, 2014
7.2 Dry Eye Drugs: Market Trends And Developments, 2015
7.2.1 Restasis: Patent Elongations And Generic Challenges Creating Uncertainty
7.2.2 Intensifying Research Focused On Dry Eye
7.2.3 Improving Diagnostic Tools
7.3 Dry Eye Drugs: Market Forecast 2015-2025
7.3.1 Dry Eye Drugs: Changing Market Shares By Leading Drugs 2015-2025
7.4 Leading Drugs For The Treatment Of Dry Eye
7.5 Restasis (ciclosporin) – Allergan (Actavis)
7.5.1 Restasis Patent Elongation
7.5.2 Restasis: Sales Forecast 2015-2025
7.6 Refresh Brand Products – Allergan (Actavis)
7.6.1 Refresh Brand Products: Sales Forecast 2015-2025
7.7 Hyalein (hyaluronic acid) – Santen
7.7.1 Hyalein: Sales Forecast 2015-2025
7.8 Diquas (diaquafosol) – Santen
7.8.1 Diquas: Sales Forecast 2015-2025
7.9 Other Dry Eye Drugs: Sales Forecast 2015-2025
7.10 Other Ophthalmic Drugs
7.10.1 Hetlioz (tasimelteon) – Vanda Pharmaceuticals
7.10.1.1 Hetlioz: Sales Forecast 2015-2025
8. Leading National Markets For Ophthalmic Drugs, 2015-2025
8.1 The Ophthalmic Drugs Market By Region
8.1.1 The Global Distribution Of Ophthalmic Drugs In 2014
8.2 Leading National Markets: Forecast 2015-2025
8.2.1 Changing Market Shares By Region, 2015-2025
8.3 Regional Ophthalmic Drugs Markets: Analysis And Forecasts, 2015-2025
8.4 United States: The Largest Ophthalmic Drugs Market
8.4.1 How Will The Rise Of A Biosimilars Market Impact On US Ophthalmic Drugs?
8.4.2 US Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5 EU5
8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.1.1 EU5 Markets: Changing Market Shares By Country, 2015-2025
8.5.2 Germany
8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.3 France
8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.4 UK
8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.5 Italy
8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.5.6 Spain
8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2015-2025
8.6 Japan
8.6.1 The Cost Of Treatment In Japan
8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
8.6.3 Japanese Ophthalmic Drugs Market Forecast 2015-2025
8.7 China
8.7.1 Expansion Of Healthcare Coverage And Reimbursement In China
8.7.2 Price Controls And The Anhui Model
8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2015-2025
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Ophthalmic Drugs
8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.9 Russia
8.9.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.10 India
8.10.1 The Impact Of The Drug Prices Control Order On Indian Pharma
8.10.2 India’s Expansion Of Healthcare Provision
8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2015-2025
8.11 Mexico
8.11.1 Mexican Healthcare Reform: Introducing Seguro Popular
8.11.2 Are Multinationals Waking Up To Mexico’s Market Potential?
8.11.3 Mexican Ophthalmic Drugs Market: Market Forecast 2015-2025
8.12 Rest of the World
8.12.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2015-2025
9. Leading Companies In The Ophthalmic Drugs Market, 2015-2025
9.1 Ophthalmic Drugs – A Changing Market Landscape
9.1.1 Leading Companies In The Ophthalmic Drugs Market, 2015
9.1.2 Ophthalmic Drugs Market: Leading Companies Forecast 2015-2025
9.1.3 Ophthalmic Drugs: Changing Market Shares By Leading Companies 2015-2025
9.2 Novartis (Alcon)
9.2.1 Novartis: Ophthalmic Drugs Portfolio, 2015
9.2.2 Novartis: Sales Forecast 2015-2025
9.2.3 Novartis: Ophthalmic Drugs Development Pipeline, 2015
9.2.4 Novartis: Recent Developments
9.2.4.1 Novartis Restructures Following Strategic Review
9.2.4.2 Novartis Licenses Ophthotech’s Fovista
9.3 Allergan (Actavis)
9.3.1 Allergan: Ophthalmic Drugs Portfolio
9.3.2 Allergan: Recent Developments
9.3.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
9.3.2.2 How Real Is The Threat Of Generic Restasis?
9.3.2.3 Valeant’s Attempted Takeover Squashed By Actavis Bid
9.3.3 Allergan: Sales Forecast 2015-2025
9.3.4 Allergan: Ophthalmic Drugs Development Pipeline, 2015
9.4 Roche
9.4.1 Roche: Ophthalmic Drugs Portfolio, 2015
9.4.1.1 Lucentis: US Sales Forecast 2015-2025
9.4.2 Roche: Sales Forecast 2015-2025
9.4.3 Roche: Ophthalmic Drugs Development Pipeline, 2015
9.5 Santen
9.5.1 Santen: Ophthalmic Drugs Portfolio, 2015
9.5.2 Santen: Recent Developments
9.5.2.1 Santen Acquires Novagali Pharma
9.5.2.2 Santen Acquires Merck’s Ophthalmic Drugs Portfolio
9.5.3 Santen: Sales Forecast 2015-2025
9.5.4 Santen: Ophthalmic Drugs Development Pipeline, 2015
9.6 Regeneron
9.6.1 Regeneron: Ophthalmic Drugs Portfolio, 2015
9.6.2 Regeneron: Recent Developments
9.6.2.1 Expanding Indications For Eylea
9.6.2.2 Eylea/Zaltrap And The Davis-Smyth Patent Agreements
9.6.3 Regeneron: Sales Forecast 2015-2025
9.6.4 Regeneron: Ophthalmic Drugs Development Pipeline, 2015
9.7 Valeant
9.7.1 Valeant: Ophthalmic Drugs Portfolio, 2015
9.7.2 Valeant: Recent Developments
9.7.2.1 Valeant’s Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
9.7.3 Valeant: Sales Forecast 2015-2025
9.7.4 Valeant: Ophthalmic Drugs Development Pipeline, 2015
9.8 Pfizer
9.8.1 Pfizer: Ophthalmic Drugs Portfolio, 2015
9.8.1.1 Xalatan/Xalacom – Pfizer’s Leading Ophthalmic Products
9.8.1.2 Macugen – Valeant/Pfizer
9.8.2 Pfizer: Recent Developments
9.8.2.1 Pfizer Attempts to Acquire AstraZeneca
9.8.3 Pfizer: Sales Forecast 2015-2025
9.8.4 Pfizer: Ophthalmic Drugs Development Pipeline, 2015
9.9 Bayer
9.9.1 Bayer: Ophthalmic Drugs Portfolio
9.9.2 Bayer: Sales Forecast 2015-2025
9.10 Senju
9.10.1 Senju: Ophthalmic Drugs Portfolio
9.10.2 Senju: Sales Forecast 2015-2025
9.10.3 Senju: Ophthalmic Drugs Development Pipeline, 2015
9.10.3.1 Y 39983 (SNJ 1656)
9.10.3.2 Difluprednate (SJE-2079)
10. Ophthalmic Drugs: Research And Development Pipeline, 2015-2025
10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts In Retinal Disorders
10.2 Drugs For Retinal Disorders: Development Pipeline, 2015
10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
10.2.2 Retinal Disorders: Filed or Recently Launched
10.2.2.1 Compaq Sipp (conbercept) – Chengdu Kanghong Pharmaceutical
10.2.2.2 Lipidil (fenofibrate) – Abbott
10.2.2.3 Iluvien (fluocinolone) – Alimera Sciences
10.2.3 Drugs In Phase 3 Development For Retinal Disorders
10.2.3.1 Fovista and Zimura – Ophthotech Corporation
10.2.3.2 Lampalizumab (anti-Factor D Fab) – Roche
10.2.3.3 MC-1101 (hydralazine) – MacuCLEAR
10.2.3.4 Tandospirone (serotonin 1A agonist) – Alcon (Novartis)
10.2.3.5 UF-021 (unoprostone) – R-Tech Ueno
10.2.4 Drugs In Phase 2 Development For Retinal Disorders
10.2.4.1 AKB-9778 (Tie2 activator) – Aerpio Therapeutics
10.2.4.2 Luminate (ALG-1001; Integrin peptide therapy) – Allegro/Senju
10.2.4.3 AGN150998 And MP0260 (Anti-VEGF DARPins) – Allergan
10.2.4.4 AGN208397 (beclomethasone) – Allergan
10.2.4.5 CPC 551 – Colby Pharmaceutical
10.2.4.6 Darapladib And GSK933776 – GlaxoSmithKline
10.2.4.7 ESBA1008 (anti-VEGF mAb) – Alcon (Novartis)
10.2.4.8 iCo-007 (antisense inhibitor of C-raf kinase mRNA) – iCo Therapeutics
10.2.4.9 iSONEP (sonepcizumab) – Lpath
10.2.4.10 LFG316 (anti-C5 mAb) – Novartis
10.2.4.11 Novadur (Intravitreal brimonidine implant) – Allergan
10.2.4.12 Optina (danazol) – Ampio Pharmaceuticals
10.2.4.13 PF-655 (synthetic siRNA) – Quark/Pfizer
10.2.4.14 Premiplex (protein replacement therapy) – Shire
10.2.4.15 Renexus (ciliary neurotrophic factor) – Neurotech
10.2.4.16 Squalamine (anti-angiogenic drug) – OHR Pharmaceutical
10.2.4.17 Zybrestat (fosbretabulin) – Oxigene/Symphony VIDA
10.2.5 Drugs In Phase 1 And Pre-clinical Development For Retinal Disorders
10.2.5.1 BDM-E – BioDiem
10.2.5.2 NADPH Oxidase Inhibitors – Alimera Sciences
10.2.5.3 NS2 (aldehyde trap) – Aldeyra Therapeutics
10.2.5.4 PAN-90806 (topical VEGF inhibitor) – PanOptica
10.2.5.5 Plasma Kallikrein Inhibitors (KVD001) – KalVista
10.2.5.6 QLT091001 (synthetic retinoid) – QLT
10.3 Drugs For Allergic, Inflammatory And Infective Ophthalmic Conditions: Development Pipeline, 2015
10.3.1 Drugs In Phase 3 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.1.1 EGP-437 (dexamethasone) – EyeGate Pharmaceuticals
10.3.1.2 IBI-10090 and IBI-20089 – Icon Bioscience
10.3.1.3 LE-MPP (loteprednol etabonate) – Kala
10.3.2 Drugs In Phase 2 Development For Allergic, Inflammatory And Infective Ophthalmic Conditions
10.3.2.1 CF101 (adenosine A3 receptor agonist) – Can-Fite BioPharma and OphthaliX
10.3.2.2 FST-100 (povidone-iodine/dexamethasone) – ForeSight Biotherapeutics
10.3.2.3 NVC-422 (auriclosene) – NovaBay
10.3.2.4 Sarilumab – Regeneron
10.3.2.5 V404 PDS – ForSight VISION
10.3.3 Drugs In Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
10.3.3.1 Finafloxacin – MerLion Pharmaceuticals/Novartis
10.4 Drugs For Glaucoma: Development Pipeline, 2015
10.4.1 Drugs In Phase 2&3 Development For Glaucoma
10.4.1.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) – Valeant
10.4.1.2 AMA0076 (ROCK inhibitor) – Amakem
10.4.1.3 Rhopressa (AR-13324; ROCK and NET inhibitor) And Roclatan (PG324; ROCK inhibitor) – Aerie Pharmaceuticals
10.4.2 Drugs In Phase 1 And Pre-clinical Development For Glaucoma
10.5 Drugs For Dry Eye: Development Pipeline, 2015
10.5.1 Drugs In Phase 3 Development For Dry Eye
10.5.1.1 EBI-005 (IL-1R antagonist) – Eleven Biotherapeutics
10.5.1.2 Lifitegrast (integrin antagonist) – Shire
10.5.1.3 MIM-D3 (tyrosine kinase receptor antagonist) – Valeant
10.5.1.4 SI-614 (modified hyaluronate) – Seikagaku
10.5.2 Drugs In Phase 2 Development For Dry Eye
10.5.2.1 ESBA105 (TNF-alpha antibody) – Alcon (Novartis)
10.5.2.2 Kineret (anakinra: IL-1 receptor antagonist) – Amgen/Sobi
10.6 Other Drugs In The Development Pipeline For Ophthalmic Conditions
10.6.1 Brimonidine For Eye Whitening – Valeant
10.6.2 GS-101 (aganirsen) – Gene Signal
10.6.3 Omidria (phenylephrine/ketorolac) – Omeros
11. Qualitative Analysis Of The Ophthalmic Drugs Market, 2015-2025
11.1 Market Factors Influencing Ophthalmic Drugs
11.2 SWOT Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.2.1 Strengths
11.2.1.1 A Healthy R&D Pipeline
11.2.1.2 Advances In Drug Delivery Technologies
11.2.1.3 Support For Reimbursement And Payment Approvals
11.2.1.4 Gene Therapy And RNA Interference Technology
11.2.1.5 New Ophthalmic Therapeutic Applications For Drugs
11.2.1.6 Development Of Neuroprotective Anti-Glaucoma Medications
11.2.1.7 Biomarkers As Tools For Better Diagnosis And Treatment
11.2.2 Weaknesses
11.2.2.1 Patient Adherence To Treatment
11.2.2.2 High Treatment Burden On Patients And Healthcare Providers
11.2.2.3 Under-Diagnosis And Under-Treatment
11.2.3 Opportunities
11.2.3.1 Sustained-Release Ocular Implants
11.2.3.2 The Impact Of A Rapidly Ageing Global Population
11.2.3.3 Increasing Prevalence Of Eye Diseases And Diabetes
11.2.3.4 Glaucoma And Retinal Disorders Will Have the Most-Marked Increases In Prevalence
11.2.3.5 Unmet Clinical Need In Many Disease Areas
11.2.3.6 Economic Growth In Emerging Market Provide Opportunity For Expansion
11.2.4 Threats
11.2.4.1 Intensifying Price Regulation In The Market
11.2.4.2 Generic Competition – Likely Erosion Of Sales For Market Leading Brands
11.2.4.3 Rising Costs Of R&D
11.2.4.4 Biosimilars – A Potent Threat To Ophthalmic Drugs’ Success
11.3 Porter’s Five Force Analysis Of The Global Ophthalmic Drugs Market, 2015-2025
11.3.1 Threat of New Entrants
11.3.2 Rivalry Among Competitors
11.3.3 Power of Suppliers
11.3.4 Threat of Substitutes
11.3.5 Power of Buyers
12. Expert Opinions from Our Primary Research
12.1 Interview with Dr Patrik De Haes, CEO and Mr Wouter Piepers, Global Head Of Corporate Communications & Investor Relations At ThromboGenics nv
12.1.1 The Ophthalmic Drug Segments Presenting Growth Opportunities
12.1.2 Jetrea As A Game-Changer In The Treatment Of Vitreomacular Adhesion
12.1.3 The Need To Embrace Novel Treatments
12.1.4 Future Plans For Jetrea
12.1.5 Expanding Treatment Indications And Strategies For Maximising Product Potential
12.1.6 Will Jetrea Be A Substitute For Surgery In Vitreomacular Adhesion Patients?
12.1.7 Development Efforts For Jetrea In Retinal Vein Occlusion
12.1.8 Future Prospects For The Ophthalmic Drugs Market
12.2 Interview With A Spokesperson From Akorn Pharmaceuticals
12.2.1 New Formulation Strategies For Cosopt, Zioptan And Azasite
12.2.2 Expansion Plans For Akorn’s Ophthalmic Portfolio
12.2.3 Tackling Key Unmet Needs Within Ophthalmics
12.2.4 Akorn’s Future Plans For Growth
13. Conclusions
13.1 Overview Of Current Market Conditions And Market Forecast, 2014-2025
13.2 Leading Sectors In Ophthalmic Drugs In 2014
13.3 Leading Regions In The Ophthalmic Drugs Market In 2014
13.4 Leading Companies In The Ophthalmic Drugs Market, 2014
13.5 What Does The Future Hold For Ophthalmic Drugs?
【レポート販売概要】
■ タイトル：眼科用薬の世界市場：ドライアイ、緑内障、網膜障害、アレルギー性・炎症性・感染性眼科疾患■ 英文：Ophthalmic Drugs Market Forecast 2015-2025 : Prospects for Leading Companies in Dry Eye, Glaucoma, Retinal Disorders, Allergic, Inflammatory & Infective Drugs
■ 発行日：2015年7月
■ 調査会社：visiongain
■ 商品コード：VGAIN5072208
■ 調査対象地域：グローバル
- 化学療法誘発性好中球減少(Chemotherapy Induced Neutropenia)の治療薬パイプライン動向（2015年上半期版）Chemotherapy Induced Neutropenia - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Neutropenia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with comparative analysis at vario …
- ビックデータ分野のリーディング企業分析：富士通Big Data represents a collection of data sets so large and complex that it becomes difficult to process using on-hand database management tool. It is also unstructured, meaning that it is not tabulated, correlated, etc. (e.g. it does not have a pre-defined data model or is not organized in a pre-defined manner). Big Data technologies enable organizations to handle huge datasets and generate inform …
- 二酸化炭素（CO2）石油増進回収（EOR）の世界市場2016-2026The latest report from business intelligence provider visiongain offers in depth analysis of the global carbon dioxide (CO2) enhanced oil recovery (EOR) market. Visiongain estimates CAPEX, including investments on anthropogenic carbon capture facilities and equipment for CO2 EOR at $3.78bn in 2016. The three biggest CO2 EOR markets in terms of CAPEX, the US, Canada and China, are set to grow at le …
- DeRoyal Industries, Inc.：市場シェア分析DeRoyal Industries, Inc. Market Share Analysis Summary GlobalData’s new report, “DeRoyal Industries, Inc. Market Share Analysis” provides in-depth information on DeRoyal Industries, Inc.’s market position in the different medical equipment markets it operates in. The report provides DeRoyal Industries, Inc. market share information in two key market categories – Orthopedic Braces and Supports and …
- シリコンエラストマーの世界市場：高温加硫、室温加硫、液状シリコーンゴムThe market size of silicone elastomers is estimated to reach USD 7.94 Billion by 2021, at a CAGR of 6.49% between 2016 and 2021. Superior properties of silicone elastomers and its increasing demand from the healthcare and electrical & electronics end-use industries is driving the silicone elastomers market. LSR has properties such as low viscosity, high curing speed, and no secondary finishing req …
- 軍用オプトロニクス、監視、照準装置の世界市場：画像増強装置、赤外線装置、レーザー装置、カメラシステム等The drive towards highly advanced individual warfighter systems is currently picking up speed in both Europe and North America, where land forces are looking to equip the individual soldier with the optical devices, personnel protective equipment, and intelligence capabilities to enable them to perform on the modern battlefield. Presently, this is not a trend that is being replicated in other regi …
- Gasco Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013Gasco Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary Gasco Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key …
- 世界のエンジニアリング・プラスチック市場動向と予測(2013- 2018)Engineering plastics are the new choice of materials in various end-user industries. Engineering plastics are preferred mainly due to their properties such as high dimensional stability, good strength, high heat and chemical resistance. The engineering plastics market is growing at a robust rate and this growth is expected to continue in the foreseeable future. This growth is due to its excellent …
- 世界の通信市場：主要トレンド（OTT、M2M、ビックデータ、クラウド）OTT, M2M, Big Data and the Cloud drive the Global Telecoms IndustryThe broader telecoms environment continues to be very challenging in 2014 and looking towards 2015 there still are many technological, economic and regulatory changes that the industry faces. The market is highly competitive and ruthless with those operating in the telecoms, mobile, broadband, digital media and ICT industries alike …
- 医療パッケージングの世界市場2016-2020About Healthcare Industry The healthcare industry has observed a shift in preference from hospital care to home healthcare over the last decade. This is expected to lead to a significant growth in the demand for healthcare products during the forecast period. In addition, increased healthcare spending will drive the market. According to the Centre for Disease Control and Prevention (CDC), healthca …
- キメラ抗原受容体T細胞療法（CART）の世界市場Summary DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015” emphasizes on the currently active CAR-T cell products in research and development. The Report covers the 35+ companies which are active in this field including 14 leading companies with 35 products targeting 20 different antigens and 9 different techno …
- DS5565（神経因性疼痛）：医薬品市場予測及び分析（～2022）DS5565 (Neuropathic Pain) - Forecast and Market Analysis to 2022 Summary Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the …
- Oil India Limited：石油・ガスの開発・生産動向及びコスト分析– 2012Oil India Limited Oil & Gas Exploration and Production Operations and Cost Analysis – 2012 Summary Oil India Limited Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key ope …
- 世界の核画像装置（医療機器）市場：企業動向MediPoint: Nuclear Imaging - Current and Future Players Summary This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand …
- 世界のEPDMシールストリップ市場2015< Global EPDM Sealing Strip Industry Report 2015> is a professional and deep research report on Global and China EPDM Sealing Strip industry. For overview analysis, the report introduces EPDM Sealing Strip basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc. For international and China market anal …
